BB Biotech AG
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Investment Focus
ISIN-No. CH0038389992
BB Biotech aims to achieve an average annual double-digit return over the long term, thus outperforming the broad market indices by a significant margin. BB Biotech invests worldwide in fast growing companies developing and marketing innovative biotech drugs.
Indexed performance (as at: 23.09.2022)
Share price: CHF 52.40 (23.09.2022)
NAV: CHF 48.25 (23.09.2022)
Rolling performance (22.09.2022)
| Share price | NAV | XNBI CHF | |
| 22.09.2021 - 22.09.2022 | -35.04% | -27.04% | -24.62% |
| 22.09.2020 - 22.09.2021 | 33.94% | 27.59% | 27.59% |
| 20.09.2019 - 22.09.2020 | 12.88% | 13.19% | 18.46% |
| 21.09.2018 - 20.09.2019 | -5.80% | 0.02% | -7.57% |
Annualized performance (22.09.2022)
| Share price | NAV | XNBI CHF | |
| 1 year | -35.04% | -27.04% | -24.62% |
| 3 years | -0.60% | 1.76% | 4.43% |
| 5 years | 1.62% | 0.27% | 2.48% |
| 10 years | 16.35% | 12.94% | 10.61% |
| Since Inception p.a. | 11.55% | 11.17% | 9.24% |
Cumulative performance (22.09.2022)
| Share price | NAV | XNBI CHF | |
| 1M | -10.23% | -4.84% | -4.55% |
| YTD | -26.62% | -10.64% | -14.26% |
| 1 year | -35.04% | -27.04% | -24.62% |
| 3 years | -1.78% | 5.38% | 13.93% |
| 5 years | 8.38% | 1.38% | 13.01% |
| 10 years | 355.11% | 237.92% | 174.38% |
| Since Inception | 2'244.22% | 2'024.58% | 1'183.21% |
Annual performance
| Share price | NAV | XNBI CHF | |
| 2021 | 8.34% | -11.45% | 2.98% |
| 2020 | 19.35% | 24.26% | 15.80% |
| 2019 | 18.55% | 23.36% | 23.02% |
| 2018 | -5.21% | -14.45% | -8.00% |
Facts & Key figures
Investment Focus
BB Biotech aims to achieve an average annual double-digit return over the long term, thus outperforming the broad market indices by a significant margin. BB Biotech invests worldwide in fast growing companies developing and marketing innovative biotech drugs. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BION SW Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | AG |
Key data (31.08.2022, base currency CHF)
| Beta | 1.24 |
| Volatility | 36.80 |
| Tracking error | 14.26 |
| Active share | 82.35 |
| Correlation | 0.94 |
| Sharpe ratio | 0.34 |
| Information ratio | 0.08 |
| Jensen's alpha | -1.45 |
| No. of positions | 31 |
Portfolio as at 30.06.2022
Positions
Market capitalization
Breakdown by sector
Currency
Opportunities & Risks
Opportunities
- Unique opportunity for European investors to access the global biotech sector, a noncyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned threemember Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
The month of August was a volatile month for stock markets with geopolitical issues dominating the investor sentiment. The Nasdaq Biotech Index TR was down by 1.0% in August, BB Biotech’s net asset value was up by 3.8% (in USD) and BB Biotech´s share price decreased by 0.9% (in CHF) during the same period.
The Nasdaq Biotech Index increased substantially, by nearly 10%, in the first half of August catalyzed by the positive Phase III results announced by Alnylam in early August. These long awaited pivotal data was seen by many as the biotech event of 2022, however sector sentiment and the general stock market turned negative once again in the second half of August.
Please find below selected highlights from a few of BB Biotech´s portfolio companies:
Alnylam (+45.5%, in USD) announced on August 3 that the APOLLO-B Phase III study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint. The study also met the first secondary endpoint of change from baseline in quality of life compared to placebo. Patisiran also demonstrated an encouraging safety and tolerability profile, with deaths numerically favoring the patisiran arm in comparison to placebo. ATTR amyloidosis with cardiomyopathy is an increasingly recognized cause of heart failure, affecting greater than 250000 patients around the world. These patients have limited treatment options, and disease progression is common. Patisiran can improve the functional capacity and quality of life of patients living with this fatal, multi-system disease.
Myovant (+30.7%, in USD) announced on August 5 with its partner Pfizer that the FDA has approved Myfembree as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. Myfembree also is approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Myovant and Pfizer will continue to jointly commercialize Myfembree in the US and product is available immediately.
Moderna (-19.4%, in USD) announced on August 31 that it has received emergency use authorization (EUA) from the FDA for its BA.4/5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222. Authorization has been given for a 50 µg booster dose for adults over 18 years of age who have received either a primary series or an initial booster of any of the authorized or approved COVID-19 vaccines. The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus. This vaccine provides broader protection against Omicron variants.
We are still seeing very attractive investment opportunities in the biotech sector and the investment team will continue to seek investments in biotech companies that deploy novel approaches to create breakthrough clinical benefits for patients and society.
Past performance is not a reliable indicator of future results and can be misleading. Changes in the rate of exchange may have an adverse effect on prices and incomes. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. The reference benchmark is used for performance comparison purposes only (dividend reinvested). Show moreShow less
